US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,244.03

-0.2454-0.02%

Number of Gainers:3

Number of Losers:4

Number of Flat:- -

PE:- -

High:1,253.07

Open:1,243.41

Low:1,231.69

Close:1,244.28

Loading ...

Lilly Presents First Clinical Data for Its Investigational, Next-Generation FrΑ Targeting ADC in Platinum-Resistant Ovarian Cancer at the 2025 Asco Annual Meeting

THOMSON REUTERS

Amgen drug cuts small cell lung cancer death risk by 40%

Arvinas Shares Sink After Breast Cancer Treatment Didn't Improve Survival in Intent-to-Treat Population

GrÜNenthal: Financial Terms of Transaction Are Not Disclosed

THOMSON REUTERS

Could Viking Therapeutics Become the Next Eli Lilly?

Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance

Terrible News for Pfizer Stock Investors

Arvinas Inc - Vepdegestrant First Protac to Show Benefit in Breast Cancer

THOMSON REUTERS

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer

THOMSON REUTERS

Arvinas Inc - Nda for Vepdegestrant to Be Submitted to FDA in Second Half of 2025

THOMSON REUTERS

Arvinas Inc - Vepdegestrant Well Tolerated With Low Gi Adverse Events

THOMSON REUTERS

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

Amgen Inc. to Present at Jefferies Global Healthcare Conference

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading

MT Newswires Live

Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs

Pfizer's BRAFTOVI Combo Reduces Death Risk by Half in BRAF V600E-Mutant Metastatic Colorectal Cancer, BREAKWATER Trial Reveals

Pfizer’s Braftovi® Combination Regimen Cuts the Risk of Death in Half for Patients With Braf V600e-Mutant Metastatic Colorectal Cancer

THOMSON REUTERS

Pfizer Inc - Phase 3 Breakwater Trial Shows 51% Risk Reduction in Death Compared to Standard-of-Care Treatment

THOMSON REUTERS

2 Top Stocks to Buy With Less Than $100

Pfizer: Breakwater Survival Data Being Discussed With U.S. FDA to Support Potential Conversion to Full Approval in 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4599/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1244.0306,"timestamp":1749153599999,"preClose":1244.276,"halted":0,"volume":50089804,"delay":0,"changeRate":-0.000197,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-0.245361,"latestTime":"06-05 16:00:00 EDT","open":1243.41,"high":1253.0748,"low":1231.6943,"amount":4748391731.454928,"amplitude":0.017183,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749196800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.540783,"peRate":31.816513,"turnoverRate":0.004734,"increases":3,"decrements":4,"flats":0,"marketCap":1338695512256,"floatMarketCap":1245282095488},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1253.0748,"amplitude":0.017183,"preClose":1244.276,"low":1231.6943,"pbRate":"9.540783","latestPrice":1244.0306,"volume":50089804,"delay":0,"open":1243.41,"prevYearClose":1305.0607,"prevWeekClose":1216.6,"prevMonthClose":1216.6,"prevQuarterClose":1314.3724,"fiveDayClose":1193.2659,"twentyDayClose":1229.3689,"sixtyDayClose":1351.7712,"secType":"PLATE","market":"US","turnoverRate":0.004734,"peRate":31.816513,"marketCap":1338695512256,"floatMarketCap":1245282095488,"timestamp":1749153599999,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":3,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540407760","title":"Lilly Presents First Clinical Data for Its Investigational, Next-Generation FrΑ Targeting ADC in Platinum-Resistant Ovarian Cancer at the 2025 Asco Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540407760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540407760?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:00","pubTimestamp":1748865619,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nFWN3S305E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2360106947.USD","BK4581","LU2361044865.SGD","SGXZ31699556.SGD","LU2106854487.HKD","LU0198837287.USD","LU1280957306.USD","LU2264538146.SGD","LU0079474960.USD","LU1720051108.HKD","LU0289739699.SGD","LU0114720955.EUR","LU0094547139.USD","SG9999014880.SGD","LU1291159041.SGD","LU0323591593.USD","LU0672654240.SGD","LU0203201768.USD","BK4588","LU1548497426.USD","GB00BDT5M118.USD","LU1868836591.USD","LU1267930730.SGD","LU2471134952.CNY","LU0823416689.USD","LU0097036916.USD","SG9999013999.USD","LU2471134796.USD","SGXZ99366536.SGD","LU2237443622.USD","LU2265009873.SGD","BK4534","LU0471298777.SGD","BK4599","LU2237443382.USD","SGXZ51526630.SGD","LU0943347566.SGD","LU1023059063.AUD","LU2023250504.SGD","LU2552382058.USD","LLY","LU1366192091.USD","LU1974910355.USD","LU0109394709.USD","SG9999015978.USD","LU0256863902.USD","LU1127390331.HKD","LU2491050154.USD","SG9999014914.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2540602327","title":"Amgen drug cuts small cell lung cancer death risk by 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540602327","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540602327?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:00","pubTimestamp":1748865600,"startTime":"0","endTime":"0","summary":"Amgen drug cuts small cell lung cancer death risk by 40% Imdelltra extended median survival by over 5 months27% of Imdelltra patients had serious side effects vs 62% of chemotherapy patientsTrial resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nL2N3S10O8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU1061106388.HKD","AMGN","LU2468319806.SGD","BK4566","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","BK4599","LU2112291526.USD","SG9999001440.SGD","BK4139","BK4581","LU1023059063.AUD","BK4533","IE00BJT1NW94.SGD","LU0868494617.USD","LU0122379950.USD","LU0109394709.USD","BK4585","LU2089984988.USD","LU1571399168.USD","LU1983299246.USD","IE00B4R5TH58.HKD","LU2242652126.USD","LU2242646821.SGD","LU0289739699.SGD","IE00B2B36J28.USD","BK4534","BK4588","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2540767942","title":"Arvinas Shares Sink After Breast Cancer Treatment Didn't Improve Survival in Intent-to-Treat Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2540767942","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540767942?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:16","pubTimestamp":1748862960,"startTime":"0","endTime":"0","summary":"Shares of Arvinas fell after the company said its in-development treatment for breast cancer didn't reach statistical significance in improving progression-free survival for its intent-to-treat population.The stock declined 9.7%, to $6.50, in pre-market trading Monday. Shares ended Friday's regular session 4% lower, at $7.20, having lost about three-quarters of their value in the past year.The biotechnology said that the therapy, vepdegestrant, notched a progression-free survival rate of 3.7 months in a recent Phase 3 study, compared with a progression-free survival rate of 3.6 months for fulvestrant, an existing breast cancer treatment.Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that the therapy did demonstrate a meaningful improvement in progression-free survival among estrogen receptor 1 mutation patients.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","ARVN","LU0985481810.HKD","LU1883839398.USD","IE0002270589.USD","SG9999002232.USD","SG9999002224.SGD","BK4007","BK4534","BK4581","IE00BBT3K403.USD","LU1023059063.AUD","LU1057294990.SGD","LU1894683264.USD","BK4599","SG9999001176.SGD","SG9999013999.USD","SGXZ57979304.SGD","BK4550","BK4592","LU0306806265.USD","LU1066053197.SGD","LU0225771236.USD","IE000M9KFDE8.USD","BK4585","IE00B19Z3581.USD","LU0321505439.SGD","SG9999011175.SGD","BK4588","LU0289739699.SGD","SG9999001176.USD","LU1066051498.USD","LU0868494617.USD","LU0456855351.SGD","LU0321505868.SGD","LU1894683348.USD","LU0170899867.USD","LU0306807586.USD","BK4533","IE00BLSP4239.USD","LU0122379950.USD","LU0234572021.USD","LU0058720904.USD","LU0225284248.USD","SG9999003800.SGD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2540767827","title":"GrÜNenthal: Financial Terms of Transaction Are Not Disclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2540767827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540767827?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:07","pubTimestamp":1748862451,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nFWN3S30DF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2750360641.GBP","LU2552382215.SGD","SGXZ57979304.SGD","LU1974910355.USD","SGXZ81514606.USD","LU0354030438.USD","LU1127390331.HKD","LU2237443978.SGD","LU0289739699.SGD","SG9999015986.USD","LLY","LU1069344957.HKD","LU0466842654.USD","LU0471298777.SGD","LU1551013425.SGD","LU1720051017.SGD","LU0079474960.USD","BK4007","LU2023250504.SGD","LU0238689110.USD","LU1267930730.SGD","BK4599","IE00B1BXHZ80.USD","LU2237443895.HKD","LU0097036916.USD","LU1035775433.USD","LU0114720955.EUR","LU0708995401.HKD","LU1720051108.HKD","LU0266013472.USD","IE0009355771.USD","LU2237443382.USD","LU1868837136.USD","IE0004445239.USD","LU2471134796.USD","LU0689472784.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU2360106947.USD","LU1983299246.USD","LU1366192091.USD","LU2361044949.HKD","LU0096364046.USD","LU0256863902.USD","LU1548497426.USD","LU2237443622.USD","LU0109391861.USD","LU0256863811.USD","LU0882574139.USD","LU2471134952.CNY"],"gpt_icon":0},{"id":"2540762190","title":"Could Viking Therapeutics Become the Next Eli Lilly?","url":"https://stock-news.laohu8.com/highlight/detail?id=2540762190","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540762190?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:45","pubTimestamp":1748861100,"startTime":"0","endTime":"0","summary":"Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications.Viking Therapeutics has a weight-loss drug candidate VK2735, that aims to compete with Eli Lilly's Zepbound.The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's  Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years.Amid this estimated $100 billion opportunity, much smaller upstart Viking Therapeutics  has emerged with a promising clinical pipeline, aiming to capture a share of the weight loss and metabolic disease market with its novel dual-agonist approach. Despite a long road ahead for this clinical-stage biotech, recent data suggesting that its VK2735 candidate could rival and even outperform the leading therapies highlights the significant potential of this exciting small-cap stock.Could Viking Therapeutics be the next Eli Lilly?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/02/could-viking-therapeutics-become-next-eli-lilly/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1267930730.SGD","LU1868836591.USD","SGXZ99366536.SGD","LU2602419157.SGD","IE00B1BXHZ80.USD","LU0289739699.SGD","LU2361045086.USD","LU0256863902.USD","VKTX","LU0640476718.USD","SGXZ31699556.SGD","LU0471298694.HKD","LU2237443978.SGD","LU2089984988.USD","IE00BJT1NW94.SGD","LU2471134879.HKD","LU1983299246.USD","LU1127390331.HKD","IE00B2B36J28.USD","SG9999014914.USD","BK4599","LU1868836757.USD","LU2746668461.USD","LU2468319806.SGD","LU1623119135.USD","SG9999015978.USD","LLY","LU2237443895.HKD","LU1868837136.USD","LU2264538146.SGD","LU0203202063.USD","LU0354030438.USD","LU1035775433.USD","LU1712237335.SGD","LU0471298777.SGD","LU2491050154.USD","LU0320765992.SGD","LU0097036916.USD","SG9999001176.USD","SG9999018865.SGD","LU1093756168.USD","BK4534","LU2360106947.USD","LU2023250504.SGD","LU0106261372.USD","LU0079474960.USD","LU0114720955.EUR","LU0061475181.USD","IE00BK4W5M84.HKD"],"gpt_icon":1},{"id":"2540309837","title":"Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2540309837","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540309837?lang=en_us&edition=fundamental","pubTime":"2025-06-02 04:35","pubTimestamp":1748810121,"startTime":"0","endTime":"0","summary":"Arvinas (ARVN) and Pfizer (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arvinas-pfizer-announce-veritac-2-trial-did-not-reach-statistical-significance-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arvinas-pfizer-announce-veritac-2-trial-did-not-reach-statistical-significance-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4550","LU1894683348.USD","LU1894683264.USD","IE0002270589.USD","IE00BLSP4452.SGD","LU1883839398.USD","LU0225771236.USD","LU0122379950.USD","SG9999001176.USD","LU0868494617.USD","LU0985481810.HKD","LU1023059063.AUD","LU0321505439.SGD","BK4534","ARVN","BK4592","BK4568","LU1066051498.USD","LU0306806265.USD","IE000M9KFDE8.USD","SG9999001176.SGD","SG9999011175.SGD","BK4585","SG9999002232.USD","IE00BLSP4239.USD","SG9999013999.USD","LU0234572021.USD","LU1066053197.SGD","BK4581","BK4588","BK4599","LU0058720904.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU1057294990.SGD","BK4007","LU0306807586.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0456855351.SGD","PFE","BK4533","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0225284248.USD","LU0321505868.SGD","LU0170899867.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2540473493","title":"Terrible News for Pfizer Stock Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2540473493","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540473493?lang=en_us&edition=fundamental","pubTime":"2025-06-01 21:15","pubTimestamp":1748783700,"startTime":"0","endTime":"0","summary":"While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results.However, recent regulatory changes in the U.S. should make this franchise somewhat less lucrative.Even so, Pfizer's hopes of a comeback lie elsewhere, especially in its improving oncology unit.Looking at the bigger picturePfizer's coronavirus franchise might weaken somewhat as a result of these changes, but perhaps not significantly. The FDA's guidance is largely irrelevant to Paxlovid. We could even speculate that lower vaccination rates may actually lead to higher infection rates and more prescriptions for the medicine. Although Comirnaty's U.S. sales will be affected, the company reported just $2.004 billion in revenue from","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/01/terrible-news-for-pfizer-stock-investors/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4533","BK4534","ISBC","LU0289739699.SGD","LU0868494617.USD","IE00B19Z3B42.SGD","LU0321505439.SGD","BK4585","BK4581","LU0306806265.USD","SG9999001176.USD","BK4592","IE000M9KFDE8.USD","LU1066051498.USD","SG9999001176.SGD","IE00BLSP4239.USD","LU0306807586.USD","BK4568","SG9999002232.USD","SG9999013999.USD","LU1023059063.AUD","LU1057294990.SGD","IE00B19Z3581.USD","BK4550","BK4588","LU1066053197.SGD","LU0225771236.USD","SG9999003800.SGD","SG9999011175.SGD","LU0985481810.HKD","LU0225284248.USD","SG9999002224.SGD","LU1894683348.USD","BK4599","BK4211","LU0170899867.USD","LU0321505868.SGD","LU1894683264.USD","LU0234572021.USD","PFE","LU0058720904.USD","IE0002270589.USD","SGXZ57979304.SGD","BK4007","LU1883839398.USD","IE00BBT3K403.USD","LU0456855351.SGD","LU0122379950.USD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2539861907","title":"Arvinas Inc - Vepdegestrant First Protac to Show Benefit in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539861907","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539861907?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:00","pubTimestamp":1748692850,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUA1PFJDC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505868.SGD","SG9999002224.SGD","ARVN","IE00B19Z3581.USD","SG9999003800.SGD","LU0985481810.HKD","SGXZ57979304.SGD","PFE","LU1066053197.SGD","IE000M9KFDE8.USD","SG9999001176.SGD","LU0234572021.USD","BK4585","LU0306806265.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","BK4588","LU1894683348.USD","LU1883839398.USD","LU0225771236.USD","LU1023059063.AUD","BK4533","SG9999001176.USD","LU0306807586.USD","LU0058720904.USD","BK4592","BK4534","LU1066051498.USD","BK4550","LU0321505439.SGD","LU1057294990.SGD","LU0225284248.USD","SG9999011175.SGD","LU0868494617.USD","SG9999013999.USD","BK4568","BK4581","IE00BBT3K403.USD","LU0456855351.SGD","LU1894683264.USD","IE0002270589.USD","BK4599","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0170899867.USD","SG9999002232.USD","BK4007","LU0122379950.USD"],"gpt_icon":0},{"id":"2539786906","title":"Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786906?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:00","pubTimestamp":1748692850,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUA1PFJDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1894683264.USD","IE00B19Z3B42.SGD","BK4599","SG9999002224.SGD","IE00BLSP4452.SGD","LU0234572021.USD","SG9999001176.SGD","LU0868494617.USD","BK4585","ARVN","IE00BBT3K403.USD","BK4007","LU0122379950.USD","IE0002270589.USD","LU0321505439.SGD","LU0985481810.HKD","BK4533","SG9999013999.USD","SG9999011175.SGD","LU0170899867.USD","LU0456855351.SGD","LU1066051498.USD","SG9999001176.USD","LU0289739699.SGD","BK4588","BK4550","LU0225284248.USD","IE00BLSP4239.USD","LU0058720904.USD","LU0306806265.USD","LU1066053197.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","BK4568","BK4581","LU0306807586.USD","LU0321505868.SGD","LU1883839398.USD","LU1023059063.AUD","IE00B19Z3581.USD","LU0225771236.USD","BK4534","BK4592","SG9999002232.USD","LU1894683348.USD","PFE","LU1057294990.SGD"],"gpt_icon":0},{"id":"2539786192","title":"Arvinas Inc - Nda for Vepdegestrant to Be Submitted to FDA in Second Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786192?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:00","pubTimestamp":1748692850,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUA1PFJDC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0225284248.USD","LU1023059063.AUD","LU0321505868.SGD","LU0456855351.SGD","LU1066053197.SGD","SG9999001176.USD","BK4585","IE00BLSP4452.SGD","LU0234572021.USD","LU1894683348.USD","IE000M9KFDE8.USD","SG9999002224.SGD","LU0058720904.USD","ARVN","BK4534","LU0225771236.USD","PFE","SG9999011175.SGD","IE0002270589.USD","BK4599","LU1057294990.SGD","SG9999003800.SGD","LU0170899867.USD","LU0321505439.SGD","BK4007","LU1883839398.USD","SG9999001176.SGD","LU1066051498.USD","BK4588","SG9999002232.USD","SG9999013999.USD","BK4568","BK4533","LU0122379950.USD","BK4581","IE00BLSP4239.USD","LU0306807586.USD","LU1894683264.USD","LU0868494617.USD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","BK4592","BK4550","LU0289739699.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0306806265.USD","LU0985481810.HKD"],"gpt_icon":0},{"id":"2539478619","title":"Arvinas Inc - Vepdegestrant Well Tolerated With Low Gi Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2539478619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539478619?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:00","pubTimestamp":1748692850,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUA1PFJDC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4550","LU1894683348.USD","LU1894683264.USD","IE0002270589.USD","IE00BLSP4452.SGD","LU1883839398.USD","LU0225771236.USD","LU0122379950.USD","SG9999001176.USD","LU0868494617.USD","LU0985481810.HKD","LU1023059063.AUD","LU0321505439.SGD","BK4534","ARVN","BK4592","BK4568","LU1066051498.USD","LU0306806265.USD","IE000M9KFDE8.USD","SG9999001176.SGD","SG9999011175.SGD","BK4585","SG9999002232.USD","IE00BLSP4239.USD","SG9999013999.USD","LU0234572021.USD","LU1066053197.SGD","BK4581","BK4588","BK4599","LU0058720904.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU1057294990.SGD","BK4007","LU0306807586.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0456855351.SGD","PFE","BK4533","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0225284248.USD","LU0321505868.SGD","LU0170899867.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2539786184","title":"Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786184","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786184?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:00","pubTimestamp":1748692800,"startTime":"0","endTime":"0","summary":"Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression  May 31 (Reuters) - An experimental treatment by Pfizer PFE.N and Arvinas ARVN.O delayed progression of breast cancer by mo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nL2N3S2103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","LU1894683264.USD","ARVN","AZN.UK","LU0171293334.USD","LU0266013472.USD","LU0203347892.USD","BK4599","LU0792757196.USD","LU0969580561.USD","LU2089284900.SGD","LU2279689827.SGD","LU0321505439.SGD","LU2112291526.USD","LU1989771016.USD","LU0289739699.SGD","LU0128525929.USD","SG9999002232.USD","LU1323610961.USD","LU0077335932.USD","LU0225771236.USD","LU0823416689.USD","BK4007","LU0640478417.SGD","LU0575583348.USD","LU1983299246.USD","SGXZ57979304.SGD","03165","LU0997586432.USD","LU0310800379.SGD","LU1051770623.HKD","IE00BBT3K403.USD","LU1883839398.USD","LU0557290698.USD","LU0310799852.SGD","IE000M9KFDE8.USD","LU0310800965.SGD","LU1291159041.SGD","BK4550","LU0957799991.USD","LU1019632923.USD","LU1066051498.USD","LU1487256676.USD","PFE","LU0889565080.SGD","LU1261432733.SGD","LU0052756011.USD","LU2133065610.SGD","LU0553294199.USD","LU0823399737.USD"],"gpt_icon":1},{"id":"2539270956","title":"Amgen Inc. to Present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2539270956","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539270956?lang=en_us&edition=fundamental","pubTime":"2025-05-31 04:01","pubTimestamp":1748635277,"startTime":"0","endTime":"0","summary":"Amgen Inc. is set to present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. ET. The presentation will be made by Peter Griffith, executive vice president and chief financial officer, and Murdo Gordon, executive vice president of Global Commercial Operations. The event will be webcast live and accessible to the news media, investors, and the general public.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire  on May 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL32qvnd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0289739699.SGD","LU0889565916.HKD","LU1571399168.USD","LU2089984988.USD","IE00BJT1NW94.SGD","LU1983299246.USD","BK4533","IE00B2B36J28.USD","LU2242652126.USD","BK4599","LU0058720904.USD","LU2112291526.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2242646821.SGD","BK4566","IE0002141913.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU0320765992.SGD","LU0122379950.USD","AMGN","BK4585","BK4534","BK4581","LU1057294990.SGD","SG9999001440.SGD","IE0009355771.USD","LU1061106388.HKD","BK4588","LU0868494617.USD"],"gpt_icon":0},{"id":"2539797275","title":"European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2539797275","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539797275?lang=en_us&edition=fundamental","pubTime":"2025-05-30 23:12","pubTimestamp":1748617960,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were relatively flat Friday morning, edging 0.01% lower to 1,453.06 on the S&P Europe Select ADR Index, which ended the week up 1.4% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4117","BDRX","TRVG","BK4139","IE00BZ1G4Q59.USD","BK4208","IE00BFXG1179.USD","BK7104","BK4532","BK4548","NVO.AU","BK4547","SAP","BK4613","BK4007","BK4535","MREO","BK4077","BK4599","NOK","BNTX","NCNA","GNFT","LU0154236417.USD","AUTL","LU1093756325.SGD","BK4551","BK4568","VRNA","BK4020","IE00BMPRXN33.USD","BK4107","IE00BKVL7J92.USD","GSK","BK4585","BK4505","IE00BMPRXR70.SGD","LU1093756168.USD","SNY","SQNS","GSK.UK","BCYC","LU1829250122.USD","BK4141","AFG","NGG","BK4588","BK4023","BK4528"],"gpt_icon":1},{"id":"2539275394","title":"Ascletis Pharma Faces Legal Setback with Seven-Year Exclusion Order for ASC41 and ASC43F Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2539275394","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539275394?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:43","pubTimestamp":1748616210,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has been involved in legal proceedings with Viking Therapeutics, Inc. over the importation of its drug candidates, ASC41 and ASC43F. In October 2024, the United States International Trade Commission issued an initial determination finding a violation of Section 337, recommending a seven-year exclusion order for these drugs. ASC41 is developed for treating non-alcoholic steatohepatitis  and targets thyroid hormone receptor beta , while ASC43F is a fixed-dose combination targeting both THRβ and farnesoid X receptor  for NASH treatment. Despite the ruling, Ascletis believes the outcome will not have a material adverse effect on its business and is seeking legal advice for an appeal. The company is committed to protecting its trade secrets and will provide updates on any significant developments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL48bdv9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1574","BK4139","BK4588","BK1161","VKTX","BK1515","BK4599","BK4585"],"gpt_icon":0},{"id":"2539722463","title":"Pfizer's BRAFTOVI Combo Reduces Death Risk by Half in BRAF V600E-Mutant Metastatic Colorectal Cancer, BREAKWATER Trial Reveals","url":"https://stock-news.laohu8.com/highlight/detail?id=2539722463","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539722463?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:01","pubTimestamp":1748606490,"startTime":"0","endTime":"0","summary":"Pfizer's BRAFTOVI Combo Reduces Death Risk by Half in BRAF V600E-Mutant Metastatic Colorectal Cancer, BREAKWATER Trial Reveals. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire  on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"82b453f3c55aa623ccd5280b27914b5b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL1j4dkG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","IE0002270589.USD","LU0225284248.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU1057294990.SGD","LU0122379950.USD","LU0225771236.USD","BK4599","BK4568","IE00BLSP4452.SGD","BK4588","LU1066051498.USD","BK4534","LU1883839398.USD","BK4592","SG9999003800.SGD","BK4007","LU0306807586.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","SG9999002224.SGD","LU0456855351.SGD","LU0321505439.SGD","LU1066053197.SGD","SG9999002232.USD","BK4533","LU1023059063.AUD","SG9999011175.SGD","IE00B19Z3B42.SGD","SG9999013999.USD","LU0321505868.SGD","IE00BBT3K403.USD","LU0868494617.USD","SG9999001176.SGD","LU0306806265.USD","LU0985481810.HKD","SGXZ57979304.SGD","LU1894683348.USD","BK4585","LU0170899867.USD","BK4581","PFE","LU0058720904.USD","LU1894683264.USD","LU0289739699.SGD","BK4550"],"gpt_icon":1},{"id":"2539248192","title":"Pfizer’s Braftovi® Combination Regimen Cuts the Risk of Death in Half for Patients With Braf V600e-Mutant Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539248192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539248192?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"82b453f3c55aa623ccd5280b27914b5b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA5DB8B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0225771236.USD","LU0456855351.SGD","IE0002270589.USD","LU1894683348.USD","SGXZ57979304.SGD","LU1057294990.SGD","IE00B19Z3581.USD","BK4588","IE00B19Z3B42.SGD","SG9999013999.USD","BK4550","LU0289739699.SGD","LU0234572021.USD","LU0321505439.SGD","PFE","SG9999001176.USD","BK4534","SG9999003800.SGD","LU0306807586.USD","SG9999002232.USD","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4581","LU0225284248.USD","BK4599","BK4007","LU1023059063.AUD","LU0122379950.USD","LU0306806265.USD","LU0170899867.USD","SG9999011175.SGD","IE00BLSP4452.SGD","LU0058720904.USD","BK4585","LU0321505868.SGD","BK4533","LU0985481810.HKD","BK4592","LU1066051498.USD","IE00BBT3K403.USD","LU1883839398.USD","SG9999001176.SGD","SG9999002224.SGD","LU1894683264.USD","LU0868494617.USD","LU1066053197.SGD","BK4568"],"gpt_icon":0},{"id":"2539224641","title":"Pfizer Inc - Phase 3 Breakwater Trial Shows 51% Risk Reduction in Death Compared to Standard-of-Care Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2539224641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539224641?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA5DB8B7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0306807586.USD","IE00BLSP4452.SGD","LU1066051498.USD","BK4581","IE000M9KFDE8.USD","BK4599","SG9999001176.SGD","IE0002270589.USD","SG9999002224.SGD","LU0225771236.USD","LU0225284248.USD","LU0058720904.USD","SG9999011175.SGD","LU0985481810.HKD","SG9999013999.USD","PFE","LU0170899867.USD","LU1883839398.USD","LU0289739699.SGD","SGXZ57979304.SGD","LU0321505439.SGD","BK4585","BK4007","BK4534","SG9999002232.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","SG9999001176.USD","LU0321505868.SGD","BK4592","IE00BLSP4239.USD","LU1894683348.USD","LU1057294990.SGD","BK4533","LU1066053197.SGD","LU0456855351.SGD","BK4568","SG9999003800.SGD","LU1023059063.AUD","LU0306806265.USD","IE00BBT3K403.USD","BK4550","LU0234572021.USD","LU1894683264.USD","BK4588","LU0122379950.USD","LU0868494617.USD"],"gpt_icon":0},{"id":"2539247832","title":"2 Top Stocks to Buy With Less Than $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2539247832","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539247832?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606400,"startTime":"0","endTime":"0","summary":"Novo Nordisk should perform well thanks to new leadership and a strong underlying business.Exelixis' main oncology franchise is safe for now even as it seeks to develop newer products.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/30/2-top-stocks-to-buy-with-less-than-100/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00BKVL7J92.USD","LU1093756325.SGD","NVO","BK4599","LU0154236417.USD","BK4585","BK4007","BK4532","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4588"],"gpt_icon":0},{"id":"2539224842","title":"Pfizer: Breakwater Survival Data Being Discussed With U.S. FDA to Support Potential Conversion to Full Approval in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539224842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539224842?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nP8N3NL004:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0306806265.USD","LU1894683264.USD","BK4568","BK4599","BK4534","LU0321505439.SGD","LU0321505868.SGD","LU0289739699.SGD","SG9999002232.USD","LU0985481810.HKD","SG9999001176.USD","BK4533","LU0225771236.USD","BK4007","IE0002270589.USD","LU0225284248.USD","SG9999011175.SGD","LU0058720904.USD","SGXZ57979304.SGD","SG9999002224.SGD","SG9999001176.SGD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0456855351.SGD","LU0170899867.USD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1883839398.USD","BK4588","BK4585","LU1066053197.SGD","LU0234572021.USD","LU0306807586.USD","IE000M9KFDE8.USD","BK4581","IE00BLSP4239.USD","LU1894683348.USD","BK4592","BK4550","LU1066051498.USD","IE00B19Z3581.USD","PFE","LU0868494617.USD","LU1057294990.SGD","LU0122379950.USD","SG9999013999.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":90,"code":"91000000","status":"200"}]}}